Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 27, 2017 16:05 ET | Source: Dermira, Inc.

Dermira Data from DRM04 and Olumacostat Glasaretil Clinical Programs to Be Presented at American Academy of Dermatology Annual Meeting

MENLO PARK, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
February 22, 2017 16:36 ET | Source: Dermira, Inc.

Dermira to Report Fourth Quarter and Full Year 2016 Financial Results

MENLO PARK, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
February 08, 2017 16:05 ET | Source: Dermira, Inc.

Dermira to Present at Leerink Partners 6th Annual Global Healthcare Conference

MENLO PARK, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
January 19, 2017 02:00 ET | Source: Dermira, Inc.

Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque Psoriasis

CIMPACT results confirm data from two previously reported Phase 3 CIMZIA trialsSubmission of marketing applications to regulatory authorities expected in third quarter of 2017 BRUSSELS, Belgium and...
January 06, 2017 07:30 ET | Source: Dermira, Inc.

Dermira Provides Corporate Update

Treatment period for DRM04 ARIDO trial completedPhase 3 acne clinical program for olumacostat glasaretil initiatedTopline data for third and final CIMZIA® (certolizumab pegol) Phase 3 trial expected...
January 05, 2017 07:30 ET | Source: Dermira, Inc.

Lori Lyons-Williams Joins Dermira as Chief Commercial Officer

Previously served at Allergan as a Vice President for Sales & Marketing, member of Operational Leadership TeamWorked on several leading dermatology brands including ACZONE® and BOTOX® during...
January 04, 2017 16:05 ET | Source: Dermira, Inc.

Dermira Elects Emmanuel Caeymaex to Board of Directors

MENLO PARK, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
January 03, 2017 07:30 ET | Source: Dermira, Inc.

Dermira Initiates Phase 3 Clinical Program in Acne

First patients dosed in Phase 3 program evaluating olumacostat glasaretil, a novel topical molecule, in patients with acne vulgarisTwo Phase 3 trials expected to enroll a total of 1,400...
December 08, 2016 02:00 ET | Source: Dermira, Inc.

Second CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis

Topline results from CIMPASI-1, the second of three Phase 3 trials in psoriasis clinical development programFindings confirm CIMZIA results observed in earlier CIMPASI-2 trialResults from third and...
November 09, 2016 16:05 ET | Source: Dermira, Inc.

Dermira to Present at Stifel 2016 Healthcare Conference

MENLO PARK, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right